Objective The aim of this study is to review the available data on efficacy and tolerability of tazarotene 0.045% lotion. Data Sources A literature search of MEDLINE (PubMed) and EMBASE databases was completed in November 2021. Study Selection and Data Extraction Articles that discussed efficacy, tolerability, and pharmacology of tazarotene 0.045% lotion, written in English and published before mid-November 2021, were assessed. Data Synthesis In two, 12-week phase III clinical trials, tazarotene 0.045% lotion had higher rates of treatment success (study 1: 25.5% and study 2: 29.6%) than individuals who received the vehicle (study 1: 13.0% and study 2: 17.3%) (both Ps < 0.001). Participants treated with tazarotene 0.045% lotion had greater least squares mean reduction in inflammatory (study 1: 55.5% and study 2: 59.5%) and noninflammatory (study 1: 51.4% and study 2: 60%) acne lesions when compared with vehicle (inflammatory acne lesions, study 1: 45.7% and study 2:49%; noninflammatory acne lesions, study 1: 41.5% and study 2: 41.6%) ( P < 0.001 for studies 1 and 2). Tazarotene 0.045% lotion was well tolerated. Relevance to Patient Care and Clinical Practice Retinoids are first-line therapy in the treatment of acne vulgaris. However, many patients experience cutaneous irritation, which can decrease patient adherence and efficacy. Tazarotene 0.045% lotion is the first retinoid to utilize polymeric emulsion technology (PET) to efficiently distribute the medication across the skin, decreasing adverse effects while maintaining efficacy. Conclusions Tazarotene 0.045% lotion is an effective and well-tolerated retinoid recently approved by the US Food and Drug Administration (FDA) for treating acne vulgaris in individuals 9 years of age and older.
Photodermatoses represent a heterogeneous group of skin disorders that are provoked by ultraviolet radiation (UVR) or visible light exposure. 1 Polymorphous light eruption (PMLE) is the most common photosensitivity disorder, and previously was more commonly reported in women with light skin phototypes aged 20-30 years. 2 Clinically, PMLE is characterized by recurrent, delayed reactions to sunlight, ranging from erythematous papules, papulovesicles, and plaques to erythema multiforme-like lesions on sun-exposed surfaces. The same morphology tends to occur in the same individual. Although the estimated worldwide prevalence ranges from 10% to 20%, with higher rates reported at higher altitudes and in western countries, the occurrence of PMLE in dark-skinned individuals has now been
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.